Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
Gynecologic Oncology
|
May 24, 2025
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer
Jung-Yun Lee, Sathana Boonyapipat, Guangwen Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 2021
Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Xiaohua Wu, Jianqing Zhu, Jing Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2022
Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
Qinglei Gao, Jianqing Zhu, Weidong Zhao, et al.
Communications Medicine
|
April 21, 2026
Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study
Xiaohua Wu, Danbo Wang, Jing Wang, et al.
The New England Journal of Medicine
|
October 15, 2025
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer
Hua Tu, He Huang, Yanfang Li, et al.
BMC Medicine
|
May 16, 2024
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Huayi Li, Zikun Peng, Jianqing Zhu, et al.
Eclinicalmedicine
|
May 15, 2024
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial
Xiaohua Wu, Jianqing Zhu, Rutie Yin, et al.
BMC Cancer
|
December 5, 2022
Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial
Yingjie Hu, Yingyan Han, Yuanming Shen, et al.
Nature Communications
|
December 21, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial
Xiaohua Wu, Jing Wang, Danbo Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
Lingfang Xia, Keqiang Zhang, Ying Tang, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
Gynecologic Oncology
|
May 24, 2025
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer
Jung-Yun Lee, Sathana Boonyapipat, Guangwen Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 2021
Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Xiaohua Wu, Jianqing Zhu, Jing Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2022
Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
Qinglei Gao, Jianqing Zhu, Weidong Zhao, et al.
Communications Medicine
|
April 21, 2026
Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study
Xiaohua Wu, Danbo Wang, Jing Wang, et al.
The New England Journal of Medicine
|
October 15, 2025
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer
Hua Tu, He Huang, Yanfang Li, et al.
BMC Medicine
|
May 16, 2024
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Huayi Li, Zikun Peng, Jianqing Zhu, et al.
Eclinicalmedicine
|
May 15, 2024
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial
Xiaohua Wu, Jianqing Zhu, Rutie Yin, et al.
BMC Cancer
|
December 5, 2022
Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial
Yingjie Hu, Yingyan Han, Yuanming Shen, et al.
Nature Communications
|
December 21, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial
Xiaohua Wu, Jing Wang, Danbo Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
Lingfang Xia, Keqiang Zhang, Ying Tang, et al.
Page
of 9